Vendor review
Ameano Peptides is graded B+ (83/100). It passed the trust floor (a score of at least 70 with testing, transparency and catalog data all observed), so its offers can be picks. We track 58 offers from Ameano Peptides. Prices last checked Nov 14, 2026.
Prices checked · Picks as of · Grade evidence cutoff
Price position
Cheaper than the median on 30 of 58 products that other tracked vendors also sell; above it on 18 and at it on 10. Prices are effective single-package prices; the median covers every tracked offer for the same product.
| Product | Ameano Peptides price | Median of tracked offers | Position | Pick |
|---|---|---|---|---|
| 5-Amino-1MQ 50 mg vial | $68 | $68.5014 offers | 1% below the median | Pick 2 |
| Adamax 10 mg vial | $108 | $69.9911 offers | 54% above the median | |
| AOD-9604 2 mg vial | $38 | $384 offers | At the median | Pick 1 |
| AOD-9604 5 mg vial | $58 | $4525 offers | 29% above the median | |
| ARA-290 10 mg vial | $48 | $4817 offers | At the median | |
| BPC-157 10 mg vial | $44 | $49.9929 offers | 12% below the median | |
| Bronchogen 10 mg vial | $58 | $582 offers | At the median | |
| Cagrilintide 10 mg vial | $88 | $89.9921 offers | 2% below the median | |
| Cagrilintide 5 mg vial | $49 | $7014 offers | 30% below the median | Pick 3 |
| Cartalax 10 mg vial | $58 | $583 offers | At the median | Pick 1 |
| CJC-1295 5 mg vial | $38 | $3919 offers | 3% below the median | Pick 3 |
| CJC-1295/Ipamorelin Blend 10 mg vial | $53 | $57.5020 offers | 8% below the median | |
| DSIP 10 mg vial | $58 | $4516 offers | 29% above the median | |
| Epithalon 10 mg vial | $38 | $4031 offers | 5% below the median | |
| GHK-Cu 100 mg vial | $53 | $5430 offers | 2% below the median | |
| GHK-Cu 50 mg vial | $35 | $4021 offers | 13% below the median | Pick 2 |
| Ipamorelin 10 mg vial | $44 | $5030 offers | 12% below the median | Pick 2 |
| Kisspeptin-10 10 mg vial | $48 | $4826 offers | At the median | |
| KLOW Blend (GHK-Cu/BPC-157/TB-500/KPV) 80 mg vial | $98 | $114.6034 offers | 14% below the median | |
| KPV 10 mg vial | $44 | $5034 offers | 12% below the median | |
| LL-37 10 mg vial | $80 | $787 offers | 3% above the median | |
| Melanotan I 10 mg vial | $44 | $39.9921 offers | 10% above the median | |
| Melanotan II 10 mg vial | $44 | $3537 offers | 26% above the median | |
| MOTS-c 10 mg vial | $54 | $4828 offers | 13% above the median | |
| NAD+ 250 mg vial | $44 | $442 offers | At the median | Pick 1 |
| NAD+ 500 mg vial | $68 | $62.4930 offers | 9% above the median | |
| Oxytocin 10 mg vial | $58 | $55.1310 offers | 5% above the median | Pick 2 |
| PDA (Pentadeca Arginate) 10 mg vial | $44 | $443 offers | At the median | Pick 1 |
| PT-141 (Bremelanotide) 10 mg vial | $44 | $4039 offers | 10% above the median | |
| Retatrutide 10 mg vial | $44 | $69.5010 offers | 37% below the median | Pick 3 |
| Retatrutide 12 mg vial | $52 | $88.504 offers | 41% below the median | Pick 2 |
| Retatrutide 20 mg vial | $67 | $104.998 offers | 36% below the median | Pick 3 |
| Retatrutide 24 mg vial | $80 | $112.504 offers | 29% below the median | Pick 2 |
| Retatrutide 48 mg vial | $159 | $1492 offers | 7% above the median | Pick 2 |
| Retatrutide 6 mg vial | $39 | $574 offers | 32% below the median | Pick 2 |
| Retatrutide/Cagrilintide Blend 15 mg vial | $135 | $126.502 offers | 7% above the median | Pick 2 |
| Selank 10 mg vial | $44 | $40.9034 offers | 8% above the median | |
| Selank/Semax Blend 20 mg vial | $88 | $738 offers | 21% above the median | Pick 3 |
| Semaglutide 10 mg vial | $38 | $63.209 offers | 40% below the median | Pick 2 |
| Semaglutide 5 mg vial | $29 | $508 offers | 42% below the median | Pick 2 |
| Semax 10 mg vial | $44 | $40.4028 offers | 9% above the median | |
| Sermorelin 5 mg vial | $44 | $44.5016 offers | 1% below the median | |
| SNAP-8 10 mg vial | $40 | $3520 offers | 14% above the median | |
| SS-31 (Elamipretide) 30 mg vial | $98 | $983 offers | At the median | |
| Survodutide 10 mg vial | $95 | $955 offers | At the median | |
| TB-500 10 mg vial | $48 | $5534 offers | 13% below the median | Pick 2 |
| Tesamorelin 10 mg vial | $68 | $6527 offers | 5% above the median | |
| Tesamorelin/Ipamorelin Blend 13 mg vial | $88 | $883 offers | At the median | Pick 1 |
| Thymosin Alpha-1 10 mg vial | $62 | $6530 offers | 5% below the median | |
| Thymosin Alpha-1 5 mg vial | $35 | $407 offers | 13% below the median | |
| Tirzepatide 10 mg vial | $29 | $66.508 offers | 56% below the median | Pick 2 |
| Tirzepatide 15 mg vial | $43 | $51.504 offers | 17% below the median | Pick 2 |
| Tirzepatide 20 mg vial | $51 | $834 offers | 39% below the median | Pick 2 |
| Tirzepatide 30 mg vial | $58 | $141.999 offers | 59% below the median | Pick 2 |
| Tirzepatide 60 mg vial | $91 | $203.998 offers | 55% below the median | Pick 2 |
| VIP (Vasoactive Intestinal Peptide) 10 mg vial | $58 | $5914 offers | 2% below the median | Pick 1 |
| Wolverine Blend (BPC-157/TB-500) 10 mg vial | $53 | $64.4914 offers | 18% below the median | Pick 3 |
| Wolverine Blend (BPC-157/TB-500) 20 mg vial | $88 | $84.9915 offers | 4% above the median | Pick 2 |
Picks won
Pick on 30 products as of Nov 14, 2026. A pick is one of the three lowest effective prices among offers from qualified vendors that were in stock, checked within 72 hours and backed by a COA for that product tested within 12 months.
Testing record
Of 58 tracked products: 39 with a lab-verified COA, 15 with a product COA on file, 1 with a COA for another strength and 3 with only COAs for other products. 354 public COAs from Ameano Peptides are archived; the newest was tested Jul 2, 2026. Labs named on COAs for its tracked products: Janoshik Analytical.
A COA describes the batch it names. It does not show which lot a vendor ships today, and PepGrades does not ask vendors to say.
Deals
No automatic deal from Ameano Peptides is on record.
Transparency checklist
7 of 8 public pages were found when the grade was built (evidence cutoff Sep 12, 2026). A page found is not a review of its terms; shipping fees, delivery times and refund terms are not recorded.
Grade
B+ (83/100) from the components below, with evidence up to Sep 12, 2026. Price updates do not change the grade; public discussion is not scored.